---
title: "Nystagmus Evaluation"
description: "Clinical decision support for systematic nystagmus evaluation, classification, and management"
version: "1.0"
setting: "ED, HOSP, OPD"
status: draft
tags:
  - nystagmus
  - vestibular
  - neuro-ophthalmology
  - oculomotor
  - central
  - peripheral
---

<div class="draft-warning-banner">
  <div class="icon">⚠️</div>
  <div class="content">
    <div class="title">DRAFT - Pending Review</div>
    <div class="description">This plan requires physician review before clinical use.</div>
  </div>
</div>

# Nystagmus Evaluation

**VERSION:** 1.0
**CREATED:** February 2, 2026
**STATUS:** Initial build

---

**DIAGNOSIS:** Nystagmus Evaluation

**ICD-10:** H55.00 (Unspecified nystagmus), H55.01 (Congenital nystagmus), H55.02 (Latent nystagmus), H55.09 (Other forms of nystagmus), H55.89 (Other irregular eye movements), H81.4 (Vertigo of central origin), G45.0 (Vertebro-basilar artery syndrome), R29.810 (Facial weakness), G25.3 (Myoclonus), G11.9 (Hereditary ataxia, unspecified)

**CPT CODES:** 92540 (Electronystagmography/videonystagmography), 92541 (Spontaneous nystagmus test), 92542 (Positional nystagmus test), 92544 (Optokinetic nystagmus test), 92545 (Oscillating tracking test), 92546 (Sinusoidal rotational testing), 92547 (Supplemental caloric test), 92548 (Computerized dynamic posturography), 92517 (VEMP), 92270 (Electro-oculography), 70553 (MRI brain with/without contrast), 70551 (MRI brain without contrast), 70544 (MRA head), 70547 (MRA neck), 70496 (CTA head), 70498 (CTA neck), 95816 (EEG routine), 95819 (EEG with sleep), 92557 (Audiometry), 95930 (Visual evoked potential), 99213-99215 (Outpatient E/M), 99281-99285 (ED E/M)

**SYNONYMS:** Nystagmus, involuntary eye movements, oscillopsia, nystagmus evaluation, dancing eyes, gaze-evoked nystagmus, downbeat nystagmus, upbeat nystagmus, periodic alternating nystagmus, PAN, direction-changing nystagmus, vestibular nystagmus, positional nystagmus, jerk nystagmus, pendular nystagmus, see-saw nystagmus, convergence-retraction nystagmus, acquired nystagmus

**SCOPE:** Systematic evaluation and management of acquired nystagmus in adults. Covers classification (central vs. peripheral), bedside examination techniques (HINTS exam, gaze testing, positional maneuvers), differentiation of nystagmus subtypes (gaze-evoked, downbeat, upbeat, periodic alternating, see-saw, convergence-retraction, vestibular), VNG/ENG and advanced vestibular testing, neuroimaging indications, and targeted treatment of specific nystagmus types (4-aminopyridine for downbeat nystagmus, baclofen for periodic alternating nystagmus). Excludes congenital/infantile nystagmus (brief mention), physiologic endpoint nystagmus, and comprehensive vertigo/dizziness evaluation (see Vertigo/Dizziness Evaluation template).

---

**PRIORITY KEY:** STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting

═══════════════════════════════════════════════════════════════
SECTION A: ACTION ITEMS
═══════════════════════════════════════════════════════════════

## 1. LABORATORY WORKUP

### 1A. Essential/Core Labs

| Test | ED | HOSP | OPD | Rationale | Target Finding |
|------|:--:|:----:|:---:|-----------|----------------|
| CBC (CPT 85025) | STAT | STAT | ROUTINE | Infection screening; anemia (can exacerbate dizziness/oscillopsia); baseline before treatment | Normal; infection markers; anemia correction |
| CMP (BMP + LFTs) (CPT 80053) | STAT | STAT | ROUTINE | Electrolyte abnormalities (hyponatremia causes central nystagmus); hepatic/renal dysfunction affects drug metabolism; hypomagnesemia lowers threshold | Normal; hyponatremia <130 → correct and reassess nystagmus; hepatic dysfunction → medication adjustment |
| Blood glucose (CPT 82947) | STAT | STAT | ROUTINE | Hypoglycemia can cause neurologic symptoms including nystagmus; Wernicke encephalopathy association | 70-180 mg/dL; hypoglycemia → correct; persistent low → evaluate further |
| Magnesium (CPT 83735) | STAT | STAT | ROUTINE | Hypomagnesemia causes nystagmus and cerebellar dysfunction; depleted by alcohol, diuretics, PPI use | >2.0 mg/dL; low → replete IV/PO |
| TSH (CPT 84443) | - | ROUTINE | ROUTINE | Thyroid dysfunction can affect vestibular and oculomotor function; hyperthyroidism causes tremor/jerky saccades | Normal; abnormal → thyroid evaluation |
| Thiamine (B1) level (CPT 84425) | STAT | STAT | ROUTINE | Wernicke encephalopathy (nystagmus + ataxia + confusion); ALWAYS consider in alcoholism, malnutrition, bariatric surgery, hyperemesis | Normal; **DO NOT WAIT for level before treating** — empiric thiamine if suspected |
| Anticonvulsant drug levels (if applicable) (CPT 80201-80299) | STAT | STAT | ROUTINE | Phenytoin, carbamazepine, and lacosamide toxicity cause gaze-evoked nystagmus; lithium toxicity causes downbeat nystagmus | Therapeutic range; supratherapeutic → dose reduction; toxic → hold medication |
| Ethanol level (CPT 80307) | STAT | STAT | - | Acute alcohol intoxication causes gaze-evoked and positional nystagmus; chronic alcoholism → Wernicke/cerebellar degeneration | Negative; positive → quantify; treat Wernicke empirically |

### 1B. Extended Workup (Second-line)

| Test | ED | HOSP | OPD | Rationale | Target Finding |
|------|:--:|:----:|:---:|-----------|----------------|
| Vitamin B12 (CPT 82607) | - | ROUTINE | ROUTINE | B12 deficiency causes subacute combined degeneration with ataxia and nystagmus | >300 pg/mL; low → supplement and monitor |
| Folate (CPT 82746) | - | ROUTINE | ROUTINE | Folate deficiency contributes to cerebellar dysfunction, especially in alcoholism | >4 ng/mL; low → supplement |
| Vitamin E level (CPT 82446) | - | - | ROUTINE | Vitamin E deficiency causes spinocerebellar syndrome with nystagmus; malabsorption syndromes | Normal; low → supplement and evaluate malabsorption |
| ESR (CPT 85652) / CRP (CPT 86140) | - | ROUTINE | ROUTINE | Inflammatory/autoimmune processes (MS, neurosarcoidosis, vasculitis) causing central nystagmus | Normal; elevated → autoimmune/inflammatory workup |
| ANA (CPT 86235) | - | ROUTINE | ROUTINE | Autoimmune conditions causing CNS inflammation (SLE cerebritis, neurosarcoidosis) | Negative; positive → further autoimmune serologies |
| ACE level (CPT 82164) | - | ROUTINE | ROUTINE | Neurosarcoidosis causes brainstem/cerebellar lesions with nystagmus | Normal; elevated → chest imaging, consider neurosarcoidosis |
| RPR/VDRL (CPT 86592) | - | ROUTINE | ROUTINE | Neurosyphilis causes Argyll Robertson pupils and nystagmus; tabes dorsalis | Negative; positive → FTA-ABS confirmation, CSF analysis |
| Anti-GAD65 antibodies (CPT 86235) | - | - | ROUTINE | GAD65 autoimmunity causes cerebellar ataxia with downbeat nystagmus; progressive cerebellar syndrome | Negative; positive → autoimmune cerebellar disease; consider immunotherapy |
| Paraneoplastic antibody panel (anti-Yo, anti-Hu, anti-Tr/DNER, anti-CV2, anti-mGluR1) | - | - | ROUTINE | Paraneoplastic cerebellar degeneration presents with nystagmus (often downbeat) + progressive ataxia | Negative; positive → urgent malignancy search (CT chest/abdomen/pelvis, PET) |

### 1C. Rare/Specialized (Refractory or Atypical)

| Test | ED | HOSP | OPD | Rationale | Target Finding |
|------|:--:|:----:|:---:|-----------|----------------|
| Anti-CASPR2 / Anti-LGI1 antibodies | - | - | EXT | Autoimmune encephalitis with oculomotor abnormalities; limbic encephalitis with nystagmus | Negative; positive → autoimmune encephalitis workup, immunotherapy |
| Anti-IgLON5 antibodies | - | - | EXT | Anti-IgLON5 disease causes oculomotor dysfunction including nystagmus, sleep disorder, gait ataxia | Negative; positive → sleep study, tau pathology consideration |
| Genetic testing (SCA panel, episodic ataxia genes) | - | - | EXT | Spinocerebellar ataxias (SCA1, 2, 3, 6, 7); episodic ataxia type 2 (CACNA1A); Friedreich ataxia | Specific mutations; SCA6 and EA2 both involve CACNA1A; SCA → progressive; EA2 → episodic with interictal nystagmus |
| CSF analysis (see Lumbar Puncture section) | - | EXT | EXT | MS (oligoclonal bands), neurosarcoidosis, leptomeningeal disease, CNS infection, autoimmune encephalitis | Normal in degenerative; OCBs → MS; pleocytosis → infection/inflammation; cytology → malignancy |
| Serum copper / ceruloplasmin (CPT 82525 / 82390) | - | - | EXT | Wilson disease causes wing-beating tremor and oculomotor dysfunction including nystagmus in young adults | Normal ceruloplasmin >20 mg/dL; low → 24h urine copper, slit lamp for KF rings |
| Tissue transglutaminase (tTG-IgA) (CPT 86364) | - | - | EXT | Celiac disease can cause cerebellar ataxia with nystagmus ("gluten ataxia") even without GI symptoms | Negative; positive → gluten-free diet, anti-gliadin antibodies |
| Prion protein gene (PRNM) analysis | - | - | EXT | Gerstmann-Straussler-Scheinker syndrome; genetic CJD can present with cerebellar ataxia and nystagmus | No pathogenic mutation; mutation → genetic counseling |

---

## 2. DIAGNOSTIC IMAGING & STUDIES

### 2A. Essential/First-line

| Study | ED | HOSP | OPD | Timing | Target Finding | Contraindications |
|-------|:--:|:----:|:---:|--------|----------------|-------------------|
| **Bedside nystagmus characterization** | STAT | STAT | ROUTINE | **CRITICAL first step**; systematic assessment: gaze in 9 cardinal positions, fixation removal (Frenzel goggles), head-shaking nystagmus, positional testing, HINTS exam if acute vestibular syndrome | Nystagmus pattern classification (see Section 5 — Differential Diagnosis); direction, waveform, effect of fixation, positional component | None; requires trained examiner |
| **HINTS exam (Head Impulse, Nystagmus, Test of Skew)** | STAT | STAT | - | **ONLY for acute vestibular syndrome** (continuous vertigo + nystagmus >24h); more sensitive than early MRI for posterior fossa stroke; must be performed by trained examiner | **Peripheral:** Positive HIT + unidirectional nystagmus + no skew; **Central:** Normal HIT + direction-changing/vertical nystagmus + skew deviation → STAT MRI | Cannot perform if episodic or positional nystagmus only; requires acute continuous nystagmus; examiner training required |
| MRI brain with and without contrast (CPT 70553) | URGENT | URGENT | ROUTINE | **Gold standard for central nystagmus evaluation**; includes DWI for stroke, FLAIR for demyelination, thin cuts through posterior fossa; MRI protocol should include craniocervical junction (downbeat nystagmus → Chiari malformation) | Stroke (DWI restriction); MS plaques (brainstem/cerebellum); Chiari malformation (cerebellar tonsillar herniation >5 mm); tumor (vestibular schwannoma, brainstem glioma, cerebellar metastasis); cerebellar degeneration (atrophy) | MRI-incompatible implants; severe claustrophobia; renal impairment (for gadolinium) |
| CT head without contrast (CPT 70450) | STAT | STAT | - | **NOT sensitive for posterior fossa pathology** (beam-hardening artifact); use only if MRI unavailable or for acute hemorrhage screening; does NOT rule out posterior circulation stroke or demyelination | Hemorrhage; large mass; hydrocephalus; **NEGATIVE CT does NOT exclude posterior fossa pathology** | None for non-contrast |
| MRA head and neck (CPT 70544, 70547) or CTA head/neck (CPT 70496, 70498) | URGENT | URGENT | ROUTINE | If central nystagmus with stroke concern; vertebral artery dissection; basilar artery stenosis/occlusion; vertebrobasilar insufficiency | Vertebral/basilar artery dissection; stenosis; occlusion; dolichoectasia compressing brainstem | MRA: MRI contraindications; CTA: contrast allergy, renal impairment |

### 2B. Extended

| Study | ED | HOSP | OPD | Timing | Target Finding | Contraindications |
|-------|:--:|:----:|:---:|--------|----------------|-------------------|
| Videonystagmography (VNG) (CPT 92540-92547) | - | - | ROUTINE | Comprehensive oculomotor and vestibular testing; spontaneous nystagmus, gaze testing, positional testing, Dix-Hallpike, caloric testing; quantifies nystagmus; documents central vs. peripheral patterns | Gaze-evoked nystagmus (central); unilateral caloric weakness (peripheral); direction-changing positional nystagmus (central); fixation suppression failure (central) | Perforated TM (water calorics — use air); bilateral vestibular loss limits caloric utility |
| Video head impulse test (vHIT) (CPT 92517) | - | URGENT | ROUTINE | Quantitative VOR assessment for all 6 semicircular canals; more sensitive than bedside HIT; differentiates peripheral from central vestibular lesions | Reduced VOR gain (<0.8) with corrective saccades → peripheral lesion; normal gain with central nystagmus → central lesion; canal-specific identification | Specialized equipment required |
| Audiometry (CPT 92557) | - | URGENT | ROUTINE | Hearing assessment when vestibular nystagmus present; identifies Meniere's disease, vestibular schwannoma, labyrinthitis; sudden sensorineural hearing loss is emergency | Normal (isolated nystagmus); low-frequency SNHL → Meniere's; asymmetric SNHL → vestibular schwannoma; mixed hearing loss → SSCD | Patient cooperation |
| MRI internal auditory canals (IAC protocol) (CPT 70553) | - | ROUTINE | ROUTINE | High-resolution T2 (CISS/FIESTA) for vestibular schwannoma; vascular loop compression of CN VIII; when asymmetric hearing loss or unilateral vestibular nystagmus | Vestibular schwannoma; vascular loop; arachnoid cyst | MRI contraindications |
| Dix-Hallpike maneuver (CPT 95992) | STAT | STAT | ROUTINE | When positional nystagmus suspected (BPPV); upbeat-torsional nystagmus with latency and limited duration = posterior canal BPPV | **Positive:** Upbeating-torsional nystagmus, 2-20 sec latency, <60 sec duration, fatigable → posterior canal BPPV; **Atypical:** No latency, persistent, non-fatigable → central positional nystagmus | Cervical spine instability; severe carotid stenosis (modify technique) |
| Visual evoked potential (VEP) (CPT 95930) | - | - | ROUTINE | If MS suspected; optic nerve demyelination; confirms optic nerve involvement in clinically isolated syndrome | Prolonged P100 latency → optic nerve demyelination (even subclinical); supports MS diagnosis | Patient cooperation; severe visual impairment |
| EEG (CPT 95816/95819) | - | ROUTINE | ROUTINE | If seizure-related nystagmus (oculogyric episodes) or epileptic nystagmus suspected; also if episodic nystagmus with altered awareness | Normal; epileptiform discharges; seizure-related eye deviation | None |

### 2C. Rare/Advanced

| Study | ED | HOSP | OPD | Timing | Target Finding | Contraindications |
|-------|:--:|:----:|:---:|--------|----------------|-------------------|
| Vestibular evoked myogenic potentials (VEMP) (CPT 92517) | - | - | ROUTINE | Saccular (cVEMP) and utricular (oVEMP) function; superior semicircular canal dehiscence; Meniere's disease; vestibular schwannoma | Abnormal in SSCD (enhanced cVEMP/oVEMP); reduced/absent in vestibular schwannoma; asymmetric in Meniere's | Conductive hearing loss affects testing |
| Rotary chair testing (CPT 92546) | - | - | EXT | Quantitative VOR across frequencies; bilateral vestibular hypofunction; pharmaceutical ototoxicity monitoring | Bilateral vestibular loss (reduced gain across frequencies); phase/gain abnormalities; asymmetric VOR | Specialized facility required |
| High-resolution CT temporal bones (CPT 70480) | - | - | ROUTINE | Superior semicircular canal dehiscence syndrome; cholesteatoma; temporal bone fracture; when sound/pressure-induced nystagmus | Dehiscence of superior canal; bony erosion; fracture line | Radiation exposure |
| Optical coherence tomography (OCT) | - | - | ROUTINE | Retinal nerve fiber layer thinning in chronic MS, neurodegenerative conditions; baseline for monitoring | RNFL thinning → chronic optic neuropathy; normal in acute | Patient cooperation; media opacity |
| Saccadometry / Eye movement recording | - | - | EXT | Quantitative analysis of saccades, smooth pursuit, optokinetic nystagmus; distinguish types of cerebellar oculomotor dysfunction | Saccadic dysmetria; impaired pursuit; gaze-holding failure; specific patterns for cerebellar vs. brainstem lesions | Specialized equipment |
| MRI cervical spine (CPT 72141/72156) | - | ROUTINE | ROUTINE | If downbeat nystagmus → evaluate craniocervical junction; Chiari malformation, craniocervical instability, foramen magnum lesion | Chiari I malformation (tonsillar herniation >5 mm); foramen magnum tumor; basilar invagination; syrinx | MRI contraindications |

### Lumbar Puncture

| Study | ED | HOSP | OPD | Timing | Target Finding | Contraindications |
|-------|:--:|:----:|:---:|--------|----------------|-------------------|
| LP — Selective indication | - | EXT | EXT | Indicated if MS, neurosarcoidosis, autoimmune encephalitis, CNS infection, or leptomeningeal disease suspected; NOT routine for isolated nystagmus; perform after MRI | Opening pressure normal (10-20 cm H2O); **MS:** oligoclonal bands, elevated IgG index; **Neurosarcoid:** pleocytosis, elevated protein, low glucose; **Infection:** per organism; **Autoimmune:** specific antibodies | Posterior fossa mass on imaging; elevated ICP without imaging; coagulopathy |

---

## 3. TREATMENT PROTOCOLS

### 3A. Acute/Emergent Treatment

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD |
| --- | --- | --- | --- | --- | --- | :--: | :--: | :--: |
| **Thiamine (empiric if Wernicke suspected)** | IV | Wernicke encephalopathy (nystagmus + ataxia + confusion triad; may be incomplete) | 500 mg :: IV :: TID :: **Thiamine 500 mg IV TID x 3-5 days, then 250 mg IV daily x 3-5 days, then 100 mg PO daily indefinitely**; give BEFORE glucose; [Galvin et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20459462/) | None at therapeutic doses | Monitor clinical improvement in nystagmus, ataxia, confusion; improvement within hours to days supports diagnosis; anaphylaxis rare with IV thiamine | STAT | STAT | - |
| **Correct electrolyte abnormalities** | IV | Hyponatremia, hypomagnesemia, hypocalcemia causing nystagmus | Per specific electrolyte :: IV :: - :: **Hyponatremia:** Correct slowly (max 8-10 mEq/L per 24h to avoid osmotic demyelination); **Hypomagnesemia:** MgSO4 2-4 g IV over 30-60 min then maintenance; **Hypocalcemia:** Calcium gluconate 1-2 g IV | Overcorrection of sodium → osmotic demyelination syndrome | Electrolytes q4-6h during correction; neurologic reassessment after correction | STAT | STAT | ROUTINE |
| **Discontinue/reduce offending medication** | - | Drug-induced nystagmus (anticonvulsants, lithium, sedatives, aminoglycosides) | Hold or reduce dose :: - :: - :: **Phenytoin toxicity:** Hold doses until level <20 mcg/mL; **Carbamazepine toxicity:** Hold until level <12 mcg/mL; **Lithium toxicity:** Hold; hydration; hemodialysis if severe; **Aminoglycosides:** Discontinue if vestibulotoxicity confirmed | Clinical necessity of medication; consult prescribing specialist | Drug levels; nystagmus reassessment after dose adjustment; permanent vestibulotoxicity possible with aminoglycosides | STAT | STAT | ROUTINE |
| **Rule out posterior circulation stroke** | - | Acute-onset nystagmus with ANY central features (direction-changing, vertical, gaze-evoked without drug cause, skew deviation, normal HIT) | HINTS exam :: - :: - :: **If ANY central pattern on HINTS:** STAT MRI with DWI + MRA head/neck; neurology/stroke consultation; activate stroke protocol if within window; [Kattah et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19762709/) | Cannot delay for MRI if basilar artery occlusion suspected | HINTS more sensitive than early CT or MRI for posterior fossa stroke; negative CT does NOT exclude stroke | STAT | STAT | - |
| **Vestibular suppressants (short-term symptomatic relief)** | PO/IV | Acute vestibular nystagmus with severe oscillopsia, nausea, or vertigo | 25 mg :: PO :: q8h :: **Meclizine 25 mg PO q6-8h** OR **Dimenhydrinate 50 mg PO/IV q6h** OR **Diazepam 2-5 mg PO/IV q8h** (potent vestibular suppressant); Ondansetron 4-8 mg IV/PO q8h for nausea; **SHORT-TERM ONLY (24-72h)** | Avoid in central nystagmus until etiology established; prolonged use delays vestibular compensation; sedation; anticholinergic effects in elderly | Limit to 72h maximum; taper as tolerated; early vestibular rehabilitation; avoid in suspected central cause until stroke excluded | STAT | STAT | ROUTINE |

### 3B. Type-Specific Nystagmus Treatment

#### DOWNBEAT NYSTAGMUS

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD |
| --- | --- | --- | --- | --- | --- | :--: | :--: | :--: |
| **4-Aminopyridine (4-AP, dalfampridine)** | PO | First-line for symptomatic downbeat nystagmus; potassium channel blocker that improves Purkinje cell function | 5 mg :: PO :: BID :: **4-Aminopyridine 5 mg PO BID (compounded)** or **Dalfampridine (Ampyra) 10 mg PO BID** (extended-release); [Strupp et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12847523/); [Claassen et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23460616/) | **Seizure disorder** (lowers seizure threshold); renal impairment (CrCl <50 — dose adjustment); hepatic impairment; cardiac arrhythmia (prolongs QT at supratherapeutic doses) | Seizure risk; ECG at baseline; renal function; therapeutic response assessment at 2-4 weeks; visual acuity improvement | - | URGENT | ROUTINE |
| **3,4-Diaminopyridine (3,4-DAP, amifampridine)** | PO | Alternative to 4-AP for downbeat nystagmus; lower seizure risk than 4-AP | 10 mg :: PO :: TID :: **3,4-Diaminopyridine 10 mg PO TID, titrate to max 20 mg TID (80 mg/day)**; [Kalla et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17928582/) | Seizure disorder (lower risk than 4-AP but still present); QT prolongation | Seizure monitoring; ECG; clinical response | - | ROUTINE | ROUTINE |
| **Clonazepam** | PO | Second-line for downbeat nystagmus; GABAergic effect on vestibular nuclei | 0.5 mg :: PO :: BID :: **Clonazepam 0.5 mg PO BID, titrate to max 1 mg TID**; may improve oscillopsia; [Dieterich et al. (1991)](https://pubmed.ncbi.nlm.nih.gov/2052574/) | Sedation; respiratory depression; falls in elderly; dependency with long-term use; cognitive impairment | Sedation; fall risk; respiratory status; avoid abrupt discontinuation; limit duration | - | ROUTINE | ROUTINE |
| **Baclofen** | PO | Third-line for downbeat nystagmus; GABAergic mechanism | 5 mg :: PO :: TID :: **Baclofen 5 mg PO TID, titrate to 10-20 mg TID**; less evidence than 4-AP | Renal impairment; sedation; withdrawal seizures if abruptly stopped | Sedation; muscle weakness; renal function; slow taper if discontinuing | - | ROUTINE | ROUTINE |
| **Address underlying cause** | - | Chiari malformation; craniocervical junction pathology; MS; cerebellar degeneration | Per etiology :: - :: - :: **Chiari malformation:** Neurosurgical referral for posterior fossa decompression if symptomatic; **MS:** Disease-modifying therapy; **Paraneoplastic:** Immunotherapy + malignancy treatment; **Nutritional:** Vitamin supplementation | Per specific intervention | Nystagmus may improve or persist depending on degree of irreversible cerebellar damage | - | ROUTINE | ROUTINE |

#### UPBEAT NYSTAGMUS

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD |
| --- | --- | --- | --- | --- | --- | :--: | :--: | :--: |
| **4-Aminopyridine (4-AP)** | PO | Upbeat nystagmus (less evidence than for downbeat, but reasonable trial); improves oculomotor function | 5 mg :: PO :: BID :: **4-AP 5 mg PO BID**; trial for 2-4 weeks to assess benefit; [Glasauer et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/15721220/) | Same as downbeat nystagmus section | Seizure risk; therapeutic response; ECG | - | ROUTINE | ROUTINE |
| **Baclofen** | PO | Alternative for upbeat nystagmus; GABAergic modulation | 5 mg :: PO :: TID :: **Baclofen 5-10 mg PO TID, titrate to 20 mg TID** | Same as above | Sedation; withdrawal risk | - | ROUTINE | ROUTINE |
| **Treat underlying etiology** | - | Medullary lesion (most common); Wernicke encephalopathy; MS; brainstem tumor; meningitis | Per etiology :: - :: - :: **Wernicke:** Thiamine IV (see 3A); **MS:** Steroids for acute relapse + DMT; **Tumor:** Oncologic referral; **Stroke:** Stroke protocol | Per specific treatment | Nystagmus may resolve with treatment of underlying cause, especially Wernicke and MS | STAT | STAT | ROUTINE |

#### PERIODIC ALTERNATING NYSTAGMUS (PAN)

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD |
| --- | --- | --- | --- | --- | --- | :--: | :--: | :--: |
| **Baclofen** | PO | **First-line for periodic alternating nystagmus**; GABA-B agonist disrupts the oscillatory brainstem velocity storage mechanism | 5 mg :: PO :: TID :: **Baclofen 5 mg PO TID, titrate by 5 mg every 3 days to 10-20 mg TID (max 80 mg/day)**; highly effective for PAN; [Halmagyi et al. (1980)](https://pubmed.ncbi.nlm.nih.gov/7191854/); [Leigh & Zee (2015)](https://pubmed.ncbi.nlm.nih.gov/26160853/) | Renal impairment; sedation; withdrawal seizures/hallucinations if abruptly discontinued; concurrent use of other CNS depressants | Sedation; muscle weakness; gradual taper required for discontinuation; monitor nystagmus response within 1-2 weeks | - | URGENT | ROUTINE |
| **4-Aminopyridine (4-AP)** | PO | Second-line for PAN if baclofen not tolerated or insufficient | 5 mg :: PO :: BID :: **4-AP 5 mg PO BID**; may be combined with baclofen; [Strupp et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12847523/) | Seizure disorder; renal impairment | Seizure monitoring; ECG; clinical response | - | ROUTINE | ROUTINE |
| **Memantine** | PO | Third-line for PAN; NMDA receptor antagonist affects velocity storage | 5 mg :: PO :: daily :: **Memantine 5 mg PO daily, titrate by 5 mg weekly to 10 mg BID**; limited evidence but rational mechanism | Renal impairment; seizure history | Renal function; confusion; dizziness | - | - | ROUTINE |

#### GAZE-EVOKED NYSTAGMUS

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD |
| --- | --- | --- | --- | --- | --- | :--: | :--: | :--: |
| **Remove offending agent** | - | Drug-induced gaze-evoked nystagmus (most common cause; anticonvulsants, sedatives, alcohol) | Reduce dose or discontinue :: - :: - :: **Most common cause is medication toxicity**; phenytoin, carbamazepine, lacosamide, benzodiazepines, lithium, gabapentin at supratherapeutic doses; nystagmus resolves with dose reduction | Clinical necessity of medication | Drug levels; clinical resolution typically within 24-48h of dose correction | STAT | STAT | ROUTINE |
| **4-Aminopyridine** | PO | Gaze-evoked nystagmus from cerebellar pathology (not drug-induced); improves gaze-holding function | 5 mg :: PO :: BID :: **4-AP 5 mg PO BID**; helps with cerebellar integrator dysfunction | Seizure disorder | Clinical response; seizure monitoring | - | ROUTINE | ROUTINE |
| **Treat structural cause** | - | Cerebellar lesion, brainstem lesion, MS, Chiari malformation | Per etiology :: - :: - :: MRI-guided management; neurosurgical referral for mass lesions; DMT for MS | Per specific treatment | Gaze-evoked nystagmus from structural lesions may persist despite treatment | - | ROUTINE | ROUTINE |

#### SEE-SAW NYSTAGMUS

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD |
| --- | --- | --- | --- | --- | --- | :--: | :--: | :--: |
| **Treat underlying cause** | - | Parasellar/diencephalic lesion (craniopharyngioma, pituitary macroadenoma, septo-optic dysplasia); rarely brainstem stroke | Per etiology :: - :: - :: **Parasellar mass:** Neurosurgical resection or debulking; endocrine evaluation; visual field assessment; **Stroke:** Standard stroke management | Per intervention | Visual acuity; visual fields; endocrine function; nystagmus may persist after tumor removal | - | URGENT | ROUTINE |
| **Clonazepam / Baclofen (symptomatic)** | PO | Symptomatic relief of oscillopsia from see-saw nystagmus; limited evidence | 0.5 mg :: PO :: BID :: **Clonazepam 0.5 mg PO BID** or **Baclofen 10 mg PO TID**; trial basis | Sedation; falls | Response assessment; side effects | - | ROUTINE | ROUTINE |

### 3C. Medications to AVOID or Use with Caution

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD |
| --- | --- | --- | --- | --- | --- | :--: | :--: | :--: |
| **Vestibular suppressants (prolonged use >72h)** | - | Delays central compensation; masks underlying pathology; sedation; fall risk | - | - | Limit to 48-72h for acute peripheral vestibular nystagmus; NOT indicated for central nystagmus types | - | - | - |
| **Aminoglycosides** (gentamicin, tobramycin, streptomycin) | - | Vestibulotoxic — can cause permanent bilateral vestibular hypofunction with oscillopsia; irreversible | - | - | Avoid if possible; if necessary, monitor levels strictly; stop if vestibular symptoms develop | - | - | - |
| **Phenytoin (high-dose / supratherapeutic)** | - | Nystagmus is dose-dependent toxicity sign; gaze-evoked nystagmus appears before ataxia; monitor levels | - | - | Free phenytoin level; nystagmus = early toxicity warning; reduce dose | - | - | - |
| **Lithium (supratherapeutic)** | - | Downbeat nystagmus and cerebellar toxicity; may be irreversible ("SILENT syndrome" — syndrome of irreversible lithium-effectuated neurotoxicity) | - | - | Lithium level; nystagmus in lithium-treated patient → STAT level; irreversible cerebellar damage possible | - | - | - |
| **Carbamazepine (supratherapeutic)** | - | Gaze-evoked nystagmus and ataxia at toxic levels; dose-dependent | - | - | Drug level; reduce dose; autoinduction may alter levels | - | - | - |

---

## 4. OTHER RECOMMENDATIONS

### 4A. Essential

| Recommendation | ED | HOSP | OPD | Details |
|---------------|:--:|:----:|:---:|---------|
| Systematic nystagmus characterization | STAT | STAT | ROUTINE | Document: direction, waveform (jerk vs. pendular), effect of gaze position, effect of fixation removal (Frenzel goggles), effect of convergence, effect of head position; this determines central vs. peripheral and guides workup |
| Frenzel goggles / fixation removal | STAT | STAT | ROUTINE | **Critical for evaluation**; peripheral vestibular nystagmus INCREASES with fixation removal; central nystagmus is NOT suppressed by fixation; absence of Frenzel goggles → have patient close eyes and observe for deviation, or use ophthalmoscope on one eye |
| Neurology consultation | URGENT | URGENT | ROUTINE | All central nystagmus patterns; downbeat, upbeat, see-saw, convergence-retraction, direction-changing nystagmus; gaze-evoked nystagmus without drug cause; atypical positional nystagmus |
| Neuro-ophthalmology referral | - | ROUTINE | ROUTINE | Persistent or unexplained nystagmus; oscillopsia affecting daily function; see-saw nystagmus; convergence-retraction nystagmus; complex oculomotor patterns; need for quantitative eye movement recording |
| Stroke consultation | STAT | STAT | - | If HINTS exam suggests central pattern in acute vestibular syndrome; any acute-onset central nystagmus pattern with vascular risk factors |
| ENT / Neurotology referral | - | ROUTINE | ROUTINE | Peripheral vestibular nystagmus with hearing loss; recurrent BPPV; suspected Meniere's; intratympanic therapy consideration |
| Vestibular rehabilitation referral | - | ROUTINE | ROUTINE | All patients with persistent oscillopsia or vestibular nystagmus; gaze stabilization exercises; balance training; habituation |
| Fall precautions | STAT | STAT | ROUTINE | Nystagmus with oscillopsia causes gait instability; assist with ambulation; home safety assessment; walker if needed |

### 4B. Extended

| Recommendation | ED | HOSP | OPD | Details |
|---------------|:--:|:----:|:---:|---------|
| Ophthalmology referral | - | ROUTINE | ROUTINE | Visual acuity assessment; retinal evaluation; optic disc examination; OCT if optic neuropathy suspected |
| Audiometry | - | URGENT | ROUTINE | If vestibular nystagmus with possible hearing involvement; asymmetric hearing loss → MRI IAC protocol; sudden SNHL is emergency |
| Driving restrictions | - | ROUTINE | ROUTINE | Patients with oscillopsia should not drive until symptoms stabilized or treated; severity-dependent; visual acuity testing for driving qualification |
| Patient education (oscillopsia management) | - | ROUTINE | ROUTINE | Explain nystagmus mechanism; adaptive strategies (head positioning, lighting, contrast); prism glasses if indicated; support groups |
| Low vision rehabilitation | - | - | ROUTINE | For patients with persistent oscillopsia impairing daily activities; adaptive devices; environmental modifications |
| Genetic counseling | - | - | ROUTINE | If hereditary ataxia (SCA, EA2, Friedreich) suspected or confirmed; family screening; reproductive counseling |

### 4C. Atypical/Refractory

| Recommendation | ED | HOSP | OPD | Details |
|---------------|:--:|:----:|:---:|---------|
| Optical devices (contact lenses, prisms) | - | - | EXT | Contact lenses may reduce congenital nystagmus via afferent feedback; base-out prisms exploit convergence-induced dampening in some nystagmus types |
| Botulinum toxin injection (extraocular muscles) | - | - | EXT | For intractable acquired nystagmus with disabling oscillopsia unresponsive to pharmacotherapy; retrobulbar injection; temporary effect (3-4 months); risk of ptosis, diplopia; [Leigh et al. (1992)](https://pubmed.ncbi.nlm.nih.gov/1736175/) |
| Neurosurgical evaluation | - | - | EXT | Chiari decompression for downbeat nystagmus from Chiari malformation; resection of posterior fossa tumor; brainstem lesion biopsy |
| Autoimmune workup and immunotherapy trial | - | ROUTINE | ROUTINE | If anti-GAD65, paraneoplastic, or other autoimmune etiology identified; IVIg, rituximab, or other immunotherapy based on antibody type |
| Cancer screening (paraneoplastic) | - | URGENT | URGENT | If paraneoplastic antibodies positive or high clinical suspicion; CT chest/abdomen/pelvis; PET/CT; mammography; testicular ultrasound per antibody type |

---

═══════════════════════════════════════════════════════════════
SECTION B: SUPPORTING INFORMATION
═══════════════════════════════════════════════════════════════

## 5. DIFFERENTIAL DIAGNOSIS

### Nystagmus Classification by Waveform

| Type | Waveform | Description | Common Causes |
|------|----------|-------------|---------------|
| **Jerk nystagmus** | Slow drift + fast corrective saccade | Defined by direction of fast phase; most common acquired type | Vestibular (peripheral or central), gaze-evoked, downbeat, upbeat |
| **Pendular nystagmus** | Sinusoidal oscillation (equal velocity both directions) | No fast phase; often multidirectional or circular/elliptical | MS (acquired), oculopalatal tremor, congenital/infantile |
| **Mixed** | Jerk in some positions, pendular in others | May change character with gaze direction | MS, brainstem lesions |

### Central vs. Peripheral Nystagmus

| Feature | Peripheral | Central |
|---------|-----------|---------|
| **Direction** | Unidirectional (horizontal ± torsional); fast phase beats AWAY from lesion | Direction-changing, vertical (downbeat/upbeat), purely torsional, or any direction |
| **Effect of fixation** | **SUPPRESSED** by visual fixation (decreases with fixation) | **NOT suppressed** by fixation; may increase |
| **Alexander's law** | Follows Alexander's law (increases in direction of fast phase) | May not follow Alexander's law |
| **Associated symptoms** | Vertigo (often severe), nausea, hearing loss, tinnitus | Vertigo (variable), diplopia, dysarthria, dysphagia, ataxia, focal deficits |
| **Head impulse test** | Abnormal (corrective saccade) | Normal (no saccade) |
| **Skew deviation** | Absent | May be present |
| **Duration** | Resolves over days to weeks (compensation) | May persist or be chronic |
| **Localizing value** | Ipsilateral vestibular nerve or labyrinth | Brainstem, cerebellum, or central vestibular pathways |

### Nystagmus by Type and Localization

| Nystagmus Type | Direction | Localization | Key Causes | Key Features |
|----------------|-----------|-------------|------------|--------------|
| **Downbeat nystagmus** | Fast phase downward; worst in lateral downgaze | Craniocervical junction; cerebellar flocculus/paraflocculus | Chiari malformation (most common structural); cerebellar degeneration; MS; lithium toxicity; Wernicke; anti-GAD65; paraneoplastic | Increases in lateral downgaze; oscillopsia worse looking down (e.g., reading, stairs); may have convergence-induced upbeat component |
| **Upbeat nystagmus** | Fast phase upward | Medulla (paramedian); midbrain; cerebellar vermis | Wernicke encephalopathy; brainstem stroke; MS; brainstem tumor; meningitis | May convert to downbeat; often transient; Wernicke = most treatable cause |
| **Gaze-evoked nystagmus** | Beats in direction of gaze (right-beating on right gaze, left-beating on left gaze) | Cerebellar flocculus (neural integrator); brainstem | **Drug toxicity** (most common: phenytoin, carbamazepine, alcohol, sedatives); cerebellar disease; brainstem lesion; myasthenia gravis (fatigue-related) | Symmetric = drug effect; asymmetric = structural lesion; rebound nystagmus on return to center = cerebellar |
| **Periodic alternating nystagmus (PAN)** | Horizontal jerk that reverses direction every 90-120 seconds with null periods | Cerebellar nodulus/uvula | Chiari malformation; cerebellar degeneration; MS; Creutzfeldt-Jakob disease; lithium toxicity; congenital | **Must observe for >2 minutes** to detect; can be mistaken for gaze-evoked; null period between direction changes; RESPONDS to baclofen |
| **See-saw nystagmus** | One eye rises + intorts while other falls + extorts, then reverses | Parasellar/diencephalic lesion; INC (interstitial nucleus of Cajal) | Parasellar mass (craniopharyngioma, pituitary macroadenoma); brainstem stroke; septo-optic dysplasia | Associated with bitemporal hemianopia (chiasmal compression); pendular variant = brainstem; jerk variant = diencephalic |
| **Convergence-retraction nystagmus** | Eyes converge and retract into orbits on attempted upgaze | Dorsal midbrain (pretectum) | Pineal region tumor; hydrocephalus (tectal compression); MS; brainstem stroke | Part of **Parinaud syndrome** (dorsal midbrain syndrome); associated with upgaze palsy, light-near dissociation, eyelid retraction (Collier sign) |
| **Torsional nystagmus** | Purely rotatory (no horizontal/vertical component) | Medulla (lateral medullary syndrome); midbrain | Wallenberg syndrome (lateral medullary stroke); midbrain lesion | Purely torsional = ALWAYS central; combined horizontal-torsional may be peripheral |
| **Vestibular nystagmus (peripheral)** | Horizontal-torsional, unidirectional | Peripheral vestibular apparatus or nerve | BPPV; vestibular neuritis; labyrinthitis; Meniere's disease; vestibular schwannoma | Suppressed by fixation; follows Alexander's law; positive HIT |
| **Positional nystagmus (BPPV)** | Upbeat-torsional (posterior canal); horizontal (lateral canal) | Semicircular canals (otolith displacement) | BPPV (posterior > lateral > anterior canal) | Latency (2-20 sec); limited duration (<60 sec); fatigable; triggered by specific positions |

### Red Flags Indicating Central Nystagmus

| Red Flag | Concern |
|----------|---------|
| **Direction-changing** nystagmus on gaze | Central vestibular or cerebellar lesion |
| **Vertical nystagmus** (downbeat or upbeat) | Craniocervical junction, brainstem, or cerebellar pathology |
| **Purely torsional** nystagmus | Brainstem lesion (ALWAYS central) |
| **Not suppressed** by visual fixation | Central; peripheral nystagmus always suppresses with fixation |
| **Normal head impulse test** in acute vestibular syndrome | Central cause (stroke) until proven otherwise |
| **Skew deviation** (vertical misalignment) | Brainstem lesion |
| Associated neurologic deficits (diplopia, dysarthria, dysphagia, ataxia) | Brainstem/cerebellar pathology |
| **No latency, non-fatigable** positional nystagmus | Central positional nystagmus (vs. BPPV) |
| **Rebound nystagmus** (direction reversal on return to center from eccentric gaze) | Cerebellar disease |
| **Convergence-retraction** pattern | Dorsal midbrain lesion |

---

## 6. MONITORING PARAMETERS

### ED / Acute Phase

| Parameter | Frequency | Target | Action if Abnormal |
|-----------|-----------|--------|-------------------|
| Nystagmus characterization (direction, type, fixation effect) | On presentation; after interventions | Complete classification; central vs. peripheral determination | Central features → STAT MRI; neurology/stroke consultation |
| Neurologic exam (cranial nerves, cerebellar, motor, sensory) | On presentation; q2h if central concern | No focal deficits beyond nystagmus | New deficits → stroke workup; expanding lesion |
| Vital signs | q1-2h | Stable | Hypertension → stroke concern; hypotension → volume depletion |
| Drug levels (if applicable) | On presentation | Therapeutic range | Supratherapeutic → hold/reduce medication |
| Electrolytes (Na, Mg, Ca) | On presentation; q6h if correcting | Normal | Ongoing correction per protocol |
| Visual acuity | On presentation | Baseline documentation | Reduced VA with nystagmus → urgent neuro-ophthalmology |

### Inpatient / Subacute Phase

| Parameter | Frequency | Target | Action if Abnormal |
|-----------|-----------|--------|-------------------|
| Nystagmus pattern reassessment | Daily | Improving or stable | Worsening → repeat imaging; expanding lesion; new etiology |
| Gait and balance assessment | Daily | Safe ambulation | Persistent imbalance → PT evaluation; fall precautions |
| Treatment response (4-AP, baclofen, etc.) | Daily while titrating | Reduced nystagmus intensity/oscillopsia | No response at therapeutic dose → alternative medication; reassess etiology |
| Side effects of treatment | Daily | Tolerable | Seizure (4-AP) → discontinue; sedation (baclofen/clonazepam) → reduce dose |
| MRI findings correlation | After imaging | Explains nystagmus pattern | Discordance between nystagmus and imaging → expand workup |

### Outpatient Follow-up

| Parameter | Frequency | Target | Action if Abnormal |
|-----------|-----------|--------|-------------------|
| Nystagmus reassessment | 2-4 weeks, then q3 months | Stable or improving | Progressive → repeat imaging; degenerative or autoimmune etiology |
| Visual acuity and oscillopsia severity | Each visit | Stable or improved | Worsening → medication adjustment; neuro-ophthalmology |
| Treatment efficacy and tolerability | 2-4 weeks after initiation; then q3 months | Symptom benefit; tolerable side effects | Adjust dose; switch agent; add combination therapy |
| MRI (follow-up) | 3-6 months if structural lesion; PRN if new symptoms | Stable or resolved | Growth → neurosurgical referral; new lesions → MS, metastases |
| VNG/ENG (follow-up) | 6-12 months or PRN | Quantitative improvement or stability | Progressive vestibular loss → reassess etiology |
| Vestibular rehabilitation progress | Monthly during active rehab | Functional improvement in balance and oscillopsia | Plateau → reassess; modify exercises; consider alternative approaches |

---

## 7. DISPOSITION CRITERIA

### Admission Criteria

| Level of Care | Criteria |
|---------------|----------|
| ICU / Stroke unit | Posterior circulation stroke with acute nystagmus; basilar artery occlusion; cerebellar stroke with mass effect/hydrocephalus; altered consciousness with nystagmus |
| General floor | Acute central nystagmus requiring workup (MRI, vascular imaging); Wernicke encephalopathy requiring IV thiamine; intractable nausea/vomiting/oscillopsia; new neurologic deficits with nystagmus; medication toxicity requiring monitoring |
| Observation | Acute-onset nystagmus pending MRI; nystagmus with equivocal HINTS findings; serial neurologic exams needed |

### Discharge Criteria

| Criterion | Details |
|-----------|---------|
| Etiology established or stroke excluded | Clear peripheral cause (BPPV, vestibular neuritis); OR central cause identified with treatment plan initiated; OR MRI negative with appropriate outpatient follow-up |
| Symptoms manageable | Oscillopsia tolerable; nausea controlled; no significant visual impairment affecting safety |
| Safe ambulation | Can walk safely (with or without assistance); low fall risk; adequate home support |
| Treatment initiated | Specific treatment started (4-AP for downbeat, baclofen for PAN, thiamine for Wernicke, etc.); or medication toxicity corrected |
| Education provided | Nystagmus type explained; treatment plan reviewed; when to return (worsening symptoms, new neurologic deficits, visual loss) |
| Follow-up arranged | Neurology within 1-2 weeks; neuro-ophthalmology if indicated; VNG/audiometry scheduled; vestibular PT if applicable |

### Discharge Prescriptions

| Medication | Indication | Instructions |
|-----------|------------|--------------|
| 4-Aminopyridine 5 mg (compounded) or Dalfampridine 10 mg | Downbeat nystagmus | Take BID; do not exceed prescribed dose; report seizure-like symptoms immediately |
| Baclofen 5-10 mg | PAN or symptomatic nystagmus | Take TID; titrate as directed; do NOT stop abruptly |
| Meclizine 25 mg | PRN for acute oscillopsia/vertigo (short-term) | Take q6-8h as needed; STOP after 48-72h; for short-term use only |
| Ondansetron 4-8 mg ODT | PRN nausea | Dissolve on tongue as needed |
| Thiamine 100 mg (oral) | Maintenance after IV thiamine course for Wernicke | Take daily indefinitely; continue B-vitamin supplementation |
| Clonazepam 0.5 mg | Refractory oscillopsia (specialist-initiated) | Take BID; avoid driving; do not combine with alcohol; avoid abrupt discontinuation |

---

## 8. EVIDENCE & REFERENCES

### Key Guidelines

| Guideline | Source | Year | Key Recommendation |
|-----------|--------|------|-------------------|
| Eye Movement Abnormalities in Clinical Diagnosis | [Leigh & Zee, The Neurology of Eye Movements, 5th ed.](https://pubmed.ncbi.nlm.nih.gov/26160853/) | 2015 | Comprehensive reference for nystagmus classification and localization; bedside examination techniques |
| HINTS Exam | [Kattah et al.](https://pubmed.ncbi.nlm.nih.gov/19762709/) | 2009 | HINTS more sensitive than early MRI for stroke in acute vestibular syndrome; 100% sensitivity, 96% specificity |
| BPPV Practice Guideline | [AAO-HNS (Bhattacharyya et al.)](https://pubmed.ncbi.nlm.nih.gov/28248609/) | 2017 | Dix-Hallpike gold standard for positional nystagmus diagnosis; Epley maneuver first-line for posterior canal BPPV |
| Cerebellar Nystagmus Treatment | [Strupp et al.](https://pubmed.ncbi.nlm.nih.gov/12847523/) | 2003 | 4-Aminopyridine effective for downbeat nystagmus; first randomized evidence |
| Periodic Alternating Nystagmus | [Halmagyi et al.](https://pubmed.ncbi.nlm.nih.gov/7191854/) | 1980 | Baclofen is effective treatment for PAN; landmark observation |

### Landmark Studies

| Study | Finding | Impact |
|-------|---------|--------|
| [Strupp et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12847523/) | 4-Aminopyridine (4-AP) reduced slow-phase velocity of downbeat nystagmus by ~50% and improved visual acuity in randomized crossover trial | Established 4-AP as first-line treatment for downbeat nystagmus |
| [Claassen et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23460616/) | 4-AP 5 mg TID significantly reduced downbeat nystagmus intensity and oscillopsia vs. placebo in double-blind RCT | Confirmed 4-AP efficacy; defined dosing regimen |
| [Kattah et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19762709/) | HINTS exam (Head Impulse, Nystagmus pattern, Test of Skew) was 100% sensitive and 96% specific for stroke in acute vestibular syndrome | HINTS should be performed in all acute vestibular syndrome; nystagmus pattern is key component |
| [Halmagyi et al. (1980)](https://pubmed.ncbi.nlm.nih.gov/7191854/) | Baclofen abolished periodic alternating nystagmus in patients with craniocervical junction disease | Baclofen became standard treatment for PAN |
| [Kalla et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17928582/) | 3,4-Diaminopyridine improved downbeat nystagmus with potentially better safety profile than 4-AP | Alternative aminopyridine option for downbeat nystagmus |
| [Tarnutzer et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21576300/) | Meta-analysis: Individual HINTS components — normal head impulse test most predictive of central cause in acute vestibular syndrome | Direction-changing nystagmus and normal HIT = "dangerous" signs requiring stroke workup |
| [Choi et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30341546/) | 12-20% of posterior fossa strokes missed on early MRI (<48h) but detected on repeat imaging | If high clinical suspicion (central nystagmus pattern) and initial MRI negative, repeat MRI at 48-72h |
| [Wagner et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34115410/) | Systematic review of aminopyridine treatment for cerebellar and oculomotor disorders; confirmed efficacy for downbeat nystagmus and episodic ataxia type 2 | Supports aminopyridine use across cerebellar oculomotor disorders |
| [Dieterich et al. (1991)](https://pubmed.ncbi.nlm.nih.gov/2052574/) | Clonazepam effective for downbeat nystagmus and other forms of central vestibular nystagmus | Clonazepam as second-line option for downbeat nystagmus |

### Nystagmus Drug Response Evidence

| Nystagmus Type | First-Line Treatment | Level of Evidence | Key Reference |
|----------------|---------------------|-------------------|---------------|
| Downbeat nystagmus | 4-Aminopyridine | RCT (Level I) | [Strupp et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12847523/); [Claassen et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23460616/) |
| Periodic alternating nystagmus | Baclofen | Case series (Level III) | [Halmagyi et al. (1980)](https://pubmed.ncbi.nlm.nih.gov/7191854/) |
| Upbeat nystagmus | 4-Aminopyridine (trial) | Case reports (Level IV) | [Glasauer et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/15721220/) |
| Gaze-evoked (drug-induced) | Remove offending agent | Expert consensus (Level V) | Standard practice |
| Acquired pendular (MS) | Gabapentin or memantine | RCT (Level I) | [Starck et al. (1997)](https://pubmed.ncbi.nlm.nih.gov/9109746/) |
| See-saw nystagmus | Treat underlying cause | Case reports (Level IV) | Per etiology |
| Convergence-retraction | Treat underlying cause | Expert consensus (Level V) | Per etiology |
| Vestibular (peripheral) | Treat underlying disorder | Per disorder | See Vertigo/Dizziness template |

---

## CHANGE LOG

**v1.0 (February 2, 2026)**
- Initial template creation
- Comprehensive nystagmus evaluation covering classification (central vs. peripheral), systematic bedside examination, nystagmus subtype differentiation (downbeat, upbeat, PAN, gaze-evoked, see-saw, convergence-retraction, torsional, vestibular), HINTS exam integration, VNG/ENG testing, MRI indications, and type-specific pharmacotherapy (4-AP for downbeat, baclofen for PAN)

---

## APPENDIX A: Systematic Nystagmus Bedside Examination Protocol

**Step 1: Primary Position Observation**
- Observe eyes in primary gaze (straight ahead) for 30+ seconds
- Document: presence of spontaneous nystagmus, direction, waveform (jerk vs. pendular), amplitude, frequency
- Note: Some nystagmus types (PAN) require >2 minutes of observation to detect direction reversal

**Step 2: Gaze Testing (9 Positions)**
- Test gaze in: center, right, left, up, down, right-up, right-down, left-up, left-down
- Document: gaze-evoked nystagmus (direction changes with gaze — central); Alexander's law compliance; rebound nystagmus on return to center
- Hold eccentric gaze for 20-30 seconds at each position

**Step 3: Fixation Removal (Frenzel Goggles or Equivalent)**
- Apply Frenzel goggles (+20 diopter lenses) or use infrared video goggles
- Alternative: Observe fundus with ophthalmoscope (nystagmus direction reversed on fundoscopy)
- **Key principle:** Peripheral nystagmus INCREASES; central nystagmus UNCHANGED or increases

**Step 4: Convergence Testing**
- Have patient fixate on near target (10-15 cm)
- Document effect on nystagmus (convergence dampens some nystagmus types; downbeat may reverse to upbeat; convergence-retraction nystagmus elicited by OKN drum or attempted upgaze)

**Step 5: Head-Shaking Nystagmus**
- Patient closes eyes; examiner oscillates head horizontally (~20 cycles at 2 Hz)
- Open eyes immediately after stopping; observe for nystagmus
- Positive: Nystagmus appears after head shaking → vestibular asymmetry; direction indicates side of lesion (fast phase away from lesion in acute; toward lesion in chronic compensation)

**Step 6: Head Impulse Test (HIT)**
- Patient fixates on examiner's nose
- Small, rapid, unpredictable horizontal head thrusts (10-20 degrees)
- **Abnormal (peripheral):** Corrective saccade (eyes "catch up" after thrust)
- **Normal (central concern):** Eyes stay on target without saccade

**Step 7: Positional Testing**
- Dix-Hallpike maneuver (posterior canal BPPV)
- Supine roll test (horizontal canal BPPV)
- Document: latency, duration, direction, fatigability, nystagmus pattern

**Step 8: Test of Skew (Alternate Cover Test)**
- Patient fixates on target; examiner alternately covers each eye
- Positive: Vertical refixation movement → brainstem lesion (skew deviation)

---

## APPENDIX B: Nystagmus Type Quick Reference

| If You See... | Think... | Next Step |
|---------------|----------|-----------|
| Downbeat nystagmus (worst in lateral downgaze) | Craniocervical junction; cerebellar degeneration; drug toxicity (lithium); Wernicke; anti-GAD65 | MRI brain + craniocervical junction; drug levels; thiamine; anti-GAD65; consider 4-AP |
| Upbeat nystagmus | Medullary lesion; Wernicke; MS; brainstem tumor | MRI brain; thiamine empirically; treat cause |
| Direction-changing gaze-evoked nystagmus | Drug toxicity (#1); cerebellar disease; brainstem lesion | Drug levels first; MRI if not drug-related |
| Periodic alternating nystagmus (reverses q90-120 sec) | Cerebellar nodulus lesion; Chiari; CJD; congenital | MRI brain + craniocervical junction; start baclofen |
| Purely torsional nystagmus | ALWAYS central — brainstem (lateral medullary stroke) | STAT MRI with DWI; stroke workup |
| See-saw nystagmus | Parasellar mass; diencephalic lesion | MRI with sellar/parasellar protocol; visual fields; endocrine panel |
| Convergence-retraction nystagmus | Dorsal midbrain (Parinaud syndrome); pineal tumor; hydrocephalus | MRI brain; check upgaze, pupils; neurosurgical referral |
| Unidirectional horizontal-torsional, suppressed by fixation | Peripheral vestibular (neuritis, BPPV, Meniere's) | HINTS exam; Dix-Hallpike; audiometry; treat per disorder |
| Acquired pendular nystagmus | MS (brainstem demyelination); oculopalatal tremor | MRI brain; MS workup; gabapentin or memantine trial |
| Positional with latency + fatigue (<60 sec) | BPPV (posterior or horizontal canal) | Dix-Hallpike confirms; Epley maneuver treats |
| Positional without latency, non-fatigable, persistent | Central positional nystagmus; posterior fossa lesion | MRI brain; NOT BPPV — do not perform repositioning maneuvers |

---

## APPENDIX C: 4-Aminopyridine (4-AP) Prescribing Guide

**Mechanism:** Blocks voltage-gated potassium channels (Kv1 family) → restores Purkinje cell excitability → normalizes cerebellar output to vestibular and oculomotor nuclei

**Indications:**
- Downbeat nystagmus (strongest evidence — Level I)
- Episodic ataxia type 2 (CACNA1A mutation)
- Upbeat nystagmus (limited evidence)
- Gaze-evoked nystagmus from cerebellar disease (limited evidence)

**Dosing:**
- Compounded 4-AP: 5 mg PO BID (standard); may titrate to 5 mg TID (max 15-20 mg/day)
- Dalfampridine (Ampyra, sustained-release): 10 mg PO BID (12 hours apart); do NOT crush or split extended-release tablets
- Onset of effect: 30-60 minutes; duration 4-6 hours (immediate-release), 12 hours (sustained-release)

**Contraindications:**
- Seizure disorder (absolute — lowers seizure threshold)
- CrCl <50 mL/min (dose adjustment or avoid — renally cleared)
- Concurrent use of other 4-AP formulations (overdose risk)
- Cardiac arrhythmia (QT prolongation at supratherapeutic doses)

**Monitoring:**
- ECG at baseline
- Renal function at baseline and periodically
- Clinical response assessment at 2-4 weeks (video recording of nystagmus helpful)
- Visual acuity measurement (reading chart at distance)
- Patient seizure diary

**Side Effects:** Insomnia, paresthesias, headache, dizziness, nausea, seizure (dose-dependent, typically at >20 mg/day)

---

## APPENDIX D: HINTS Exam Interpretation for Nystagmus Evaluation

**Prerequisites:**
- Patient has **ACUTE VESTIBULAR SYNDROME**: Continuous vertigo >24h, nausea/vomiting, nystagmus, gait instability
- Spontaneous nystagmus visible at rest or with fixation removed
- Examiner is trained in HINTS

| Component | Peripheral (Safe) | Central (Dangerous) |
|-----------|-------------------|---------------------|
| **Head Impulse Test** | ABNORMAL — corrective saccade (reassuring) | NORMAL — no saccade (dangerous) |
| **Nystagmus** | Unidirectional — fast phase always same direction (reassuring) | Direction-changing, vertical, or purely torsional (dangerous) |
| **Test of Skew** | Negative — no vertical misalignment (reassuring) | Positive — vertical refixation (dangerous) |

**ANY ONE central sign = Central lesion likely → STAT MRI + stroke workup**
**ALL THREE peripheral = Peripheral vestibular lesion (vestibular neuritis)**

**INFARCT Mnemonic:** **I**mpulse **N**ormal, **F**ast-phase **A**lternating, **R**efixation on cover **T**est = Central = Stroke until proven otherwise

**Important:** HINTS is ONLY valid in the acute vestibular syndrome (continuous vertigo/nystagmus >24h). It is NOT valid for episodic, positional, or chronic nystagmus.

---

*This template represents the initial build phase (Skill 1) and requires validation through the checker pipeline (Skills 2-6) before clinical deployment.*
